NCT03863145: Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors

NCT03863145
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Early Ph+ase 1
Drug Category: Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only TNBC patients are eligible for Part 2 (dose expansion phase)
Exclusions: Patients with known brain metastases or symptoms suggestive of brain metastases, spinal cord compression, carcinomatous meningitis, or leptomeningeal disease unless neurologically stable for at least 4 weeks
https://ClinicalTrials.gov/show/NCT03863145

Comments are closed.

Up ↑